Acrongenomics Inc. appoints Constantine Poulios as President
Acrongenomics Inc. Explores Novel 'Nanoweapons' in Eliminating Hospital-Related Infections
Acrongenomics, Inc. announced the appointment of Mr. Constantine Poulios, LL.M., as President. Mr. Poulios was holding the position of Vice President at Acrongenomics Inc. as of July 6, 2004. Mr. Poulios succeeds Dr. Eleftherios Georgakopoulos, who retired from the board earlier this week. The leadership change coincides with the transfer of the former president's 4 million shares to the treasury of the company, while the company keeps full title on all its technology developed to date.
Mr. Poulios has extensive experience in serving multinational companies. An attorney by education and profession, he was part of the Corporate and Tax Advisory Services of Ernst & Young before joining Acrongenomics, Inc. Mr. Poulios was managing important accounts including that of Coca Cola, Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer, GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he has also worked for Ernst & Young in the US. He obtained his Master's of Laws from Northwestern University School of Law in Chicago in 1997, while he is a 1995 graduate from the School of Law at the National University of Athens. Mr. Poulios has also been awarded with a Certificate in Law in 1993 from the School of Law at the University of Bordeaux in France and he has attended graduate courses in management in US universities.
Acrongenomics, Inc. also announced that it is currently under negotiations in order to complete a collaboration agreement with an International group of experts towards the development of unique "nanoweapons" that exhibit extraordinary properties in eliminating hospital related infections.
Other news from the department people
